Compare VAC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAC | IMNM |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.8B |
| IPO Year | 2011 | 2020 |
| Metric | VAC | IMNM |
|---|---|---|
| Price | $67.90 | $23.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $75.13 | $32.80 |
| AVG Volume (30 Days) | 452.6K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,032,000,000.00 | $6,941,000.00 |
| Revenue This Year | $54.50 | N/A |
| Revenue Next Year | $3.03 | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $44.58 | $6.97 |
| 52 Week High | $86.33 | $27.65 |
| Indicator | VAC | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 60.73 |
| Support Level | $63.47 | $19.23 |
| Resistance Level | $71.87 | $27.14 |
| Average True Range (ATR) | 3.07 | 1.16 |
| MACD | -0.24 | 0.28 |
| Stochastic Oscillator | 53.94 | 90.71 |
Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.